## Chiara Macchi

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5229186/publications.pdf

Version: 2024-02-01

38	1,436	22	37
papers	citations	h-index	g-index
38	38	38	2286
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	PCSK9 induces a pro-inflammatory response in macrophages. Scientific Reports, 2018, 8, 2267.	1.6	166
2	PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. European Heart Journal, 2019, 40, 357-368.	1.0	124
3	Liver fat accumulation is associated with circulating PCSK9. Annals of Medicine, 2016, 48, 384-391.	1.5	119
4	Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. Journal of Biological Chemistry, 2016, 291, 3508-3519.	1.6	93
5	Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus. Journal of Clinical Lipidology, 2014, 8, 61-68.	0.6	74
6	Risk identification and possible countermeasures for muscle adverse effects during statin therapy. European Journal of Internal Medicine, 2015, 26, 82-88.	1.0	67
7	Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents. European Journal of Preventive Cardiology, 2019, 26, 930-949.	0.8	64
8	Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2021, 191, 1385-1397.	1.9	62
9	Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial. European Journal of Nutrition, 2018, 57, 499-511.	1.8	49
10	Statin therapy and related risk of new-onset type 2 diabetes mellitus. European Journal of Internal Medicine, 2014, 25, 401-406.	1.0	45
11	Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Translational Research, 2016, 173, 19-29.	2.2	45
12	Appropriateness of statin prescription in the elderly. European Journal of Internal Medicine, 2018, 50, 33-40.	1.0	43
13	Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study. Nutrition Journal, 2019, 18, 13.	1.5	37
14	Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals. European Journal of Preventive Cardiology, 2019, 26, 578-588.	0.8	36
15	Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients. Aging Male, 2013, 16, 33-37.	0.9	33
16	Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance. Cardiovascular Diabetology, 2020, 19, 187.	2.7	31
17	Prognostic parameters of inâ€hospital mortality in COVIDâ€19 patients—An Italian experience. European Journal of Clinical Investigation, 2021, 51, e13629.	1.7	31
18	Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. Atherosclerosis, 2020, 309, 39-46.	0.4	29

#	Article	IF	CITATIONS
19	Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1579-1587.	1.4	28
20	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. Annals of Medicine, 2018, 50, 461-484.	1.5	28
21	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2020, 190, 2226-2236.	1.9	26
22	Hepatic steatosis and <scp>PNPLA</scp> 3 I148 <scp>M</scp> variant are associated with serum <scp>F</scp> etuinâ€ <scp>A</scp> independently of insulin resistance. European Journal of Clinical Investigation, 2014, 44, 627-633.	1.7	24
23	Theranostic Nanocages for Imaging and Photothermal Therapy of Prostate Cancer Cells by Active Targeting of Neuropeptide-Y Receptor. Bioconjugate Chemistry, 2016, 27, 2911-2922.	1.8	24
24	Body composition and metabolic changes during a 520-day mission simulation to Mars. Journal of Endocrinological Investigation, 2018, 41, 1267-1273.	1.8	20
25	Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2022, 6, 535-549.	2.0	18
26	Free and bound plasma leptin in anorexia nervosa patients during a refeeding program. Endocrine, 2016, 51, 380-383.	1.1	16
27	Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1245-1253.	1.1	16
28	PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation. Mediators of Inflammation, 2020, 2020, 1-8.	1.4	16
29	Unsaponifiable Fraction of Unripe Fruits of Olea europaea: An Interesting Source of Anti-inflammatory Constituents. Planta Medica, 2016, 82, 273-278.	0.7	13
30	Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity. Frontiers in Cardiovascular Medicine, 2021, 8, 785250.	1.1	11
31	HDL in COVID-19 Patients: Evidence from an Italian Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 5955.	1.0	9
32	Impact of Soy Î <sup>2</sup> -Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells. Nutrients, 2022, 14, 193.	1.7	9
33	Maternal exposure to air pollutants, PCSK9 levels, fetal growth and gestational age – An Italian cohort. Environment International, 2021, 149, 106163.	4.8	8
34	Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability—Evidence from ApoE-/- Mice. International Journal of Molecular Sciences, 2022, 23, 5415.	1.8	7
35	Increased circulating adiponectin in males with chronic HCV hepatitis. European Journal of Internal Medicine, 2015, 26, 635-639.	1.0	6
36	Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosisâ€"The IMPROVE Study. Biomedicines, 2021, 9, 841.	1.4	6

#	Article	IF	CITATIONS
37	Impact of Phyllantus niruri and Lactobacillus amylovorus SGL 14 in a mouse model of dietary hyperoxaluria. Beneficial Microbes, 2020, 11, 547-559.	1.0	3
38	Gold nanocages for imaging and therapy of prostate cancer cells. Proceedings of SPIE, 2016, , .	0.8	0